Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism
Neuropathic syndromes which are evoked by lesions to the peripheral or central nervous system are extremely difficult to treat, and available drugs rarely joint an antihyperalgesic with a neurorestorative effect. N-Palmitoylethanolamine (PEA) exerts antinociceptive effects in several animal models a...
Saved in:
Main Authors: | L. Di Cesare Mannelli, G. D'Agostino, A. Pacini, R. Russo, M. Zanardelli, C. Ghelardini, A. Calignano |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2013/328797 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TNF-Alpha in Peripheral Neuropathy Patients with Impaired Glucose Regulation
by: Xia Li, et al.
Published: (2017-01-01) -
Interactions between and Shared Molecular Mechanisms of Diabetic Peripheral Neuropathy and Obstructive Sleep Apnea in Type 2 Diabetes Patients
by: Hong Shen, et al.
Published: (2018-01-01) -
PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis
by: Michael K. Racke, et al.
Published: (2008-01-01) -
Progress on spinal cord stimulation in treatment of peripheral neuropathy
by: ZONG Yun⁃fei, et al.
Published: (2025-01-01) -
Peripheral neuropathy as initial manifestation of Churg-Strauss Syndrome
by: Antonio Villa, et al.
Published: (2020-03-01)